Distinguished in Generalized Resistance to Thyroid Hormone

Guang P. Wang

Bai Jia Zhuang Road No.8, 
Beijing, CN 
Distinguished in Generalized Resistance to Thyroid Hormone
Bai Jia Zhuang Road No.8, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Guang Wang practices in Beijing, China. Wang is rated as a Distinguished expert by MediFind in the treatment of Generalized Resistance to Thyroid Hormone. Their top areas of expertise are Generalized Resistance to Thyroid Hormone, Familial Hyperthyroidism due to Mutations in TSH Receptor, Hypothyroidism, and Type 2 Diabetes (T2D).

Their clinical research consists of co-authoring 182 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Generalized Resistance to Thyroid Hormone.

Locations

Bai Jia Zhuang Road No.8, Beijing, 100020, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drugs: Dulaglutide, Insulin Glargine
Study Phase: Phase 3
View 1 Less Clinical Trial

182 Total Publications

Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
Journal: Diabetes, obesity & metabolism
Published: September 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile